| |
Fig. 8.
Metalloprotease inhibitor treatment does not grossly affect growth cone morphology or the patterning or morphology of the neuroepithelium. A, B, Control (A) or 5 μM GM6001-treated (B) growth cones in culture. C–H, Cross sections through the diencephalon/midbrain regions of stage 40 embryos exposed at stage 33/34 to control (0.4% DMSO) or 10 μM GM6001 bathing solutions. In allpanels, the exposed side of the brain is on theleft, and the unexposed side is on theright. Note that the left eye is removed during the exposure. Sections were immunolabeled with markers of the neuroepithelium. C, D, Zn-12 immunolabeling of control brains (C) and brains exposed to GM6001 (D). E, β-tubulin immunoreactivity of a GM6001-treated brain. F, Islet-1 immunolabeling of ventrally located neurons (arrows) in a GM6001-treated brain showing that dorsoventral polarity is maintained. G, H, Immunolabeling of control (G) and GM6001-treated (H) brains with a rabbit polyclonal GABA antibody. GABAergic neurons found in the mid-diencephalon are present in both control and experimental brains. R, Retina;Di, diencephalon; Ve, ventricle;Mb, midbrain; D, dorsal;V, ventral. Scale bar: (in H)A, B, 10 μm; C–H, 50 μm. |
